ATE429930T1 - Verfahren zur förderung des nukleinsäuretransfers - Google Patents
Verfahren zur förderung des nukleinsäuretransfersInfo
- Publication number
- ATE429930T1 ATE429930T1 AT02741206T AT02741206T ATE429930T1 AT E429930 T1 ATE429930 T1 AT E429930T1 AT 02741206 T AT02741206 T AT 02741206T AT 02741206 T AT02741206 T AT 02741206T AT E429930 T1 ATE429930 T1 AT E429930T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- cells
- complex particles
- gene
- protein
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title abstract 13
- 102000039446 nucleic acids Human genes 0.000 title abstract 13
- 150000007523 nucleic acids Chemical class 0.000 title abstract 13
- 238000000034 method Methods 0.000 title abstract 6
- 230000001737 promoting effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 9
- 239000002245 particle Substances 0.000 abstract 8
- 102000008186 Collagen Human genes 0.000 abstract 4
- 108010035532 Collagen Proteins 0.000 abstract 4
- 229920001436 collagen Polymers 0.000 abstract 4
- 230000014509 gene expression Effects 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 238000012258 culturing Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000007790 solid phase Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001186320 | 2001-06-20 | ||
| JP2001278293 | 2001-09-13 | ||
| PCT/JP2002/006137 WO2003000297A1 (fr) | 2001-06-20 | 2002-06-20 | Procede facilitant le transfert d'acides nucleiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429930T1 true ATE429930T1 (de) | 2009-05-15 |
Family
ID=26617260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02741206T ATE429930T1 (de) | 2001-06-20 | 2002-06-20 | Verfahren zur förderung des nukleinsäuretransfers |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8742091B2 (de) |
| EP (1) | EP1407787B1 (de) |
| JP (1) | JP4081436B2 (de) |
| KR (1) | KR100888566B1 (de) |
| CN (1) | CN1313158C (de) |
| AT (1) | ATE429930T1 (de) |
| CA (1) | CA2451603C (de) |
| DE (1) | DE60232149D1 (de) |
| DK (1) | DK1407787T3 (de) |
| ES (1) | ES2324525T3 (de) |
| PT (1) | PT1407787E (de) |
| WO (1) | WO2003000297A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5118285B2 (ja) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | オリゴヌクレオチド導入製剤 |
| ATE429930T1 (de) | 2001-06-20 | 2009-05-15 | Dainippon Sumitomo Pharma Co | Verfahren zur förderung des nukleinsäuretransfers |
| WO2005061717A1 (ja) * | 2003-12-19 | 2005-07-07 | Dainippon Sumitomo Pharma Co., Ltd. | 新規な核酸導入法 |
| EP1715052A4 (de) * | 2004-01-29 | 2007-10-03 | Nat Inst Of Advanced Ind Scien | Zusammensetzung und verfahren zur erhöhung der gentransfereffizienz |
| JP2007267602A (ja) * | 2004-06-25 | 2007-10-18 | National Institute Of Advanced Industrial & Technology | 固相上で細胞に核酸を導入し、かつ、この細胞を分化誘導させるための方法および組成物 |
| JP4585242B2 (ja) * | 2004-06-29 | 2010-11-24 | 株式会社高研 | 核酸導入用セルトランスフェクションアレイ |
| US20090062184A1 (en) * | 2005-03-24 | 2009-03-05 | Dainippon Sumitomo Pharma Co., Ltd. | Fine particulate preparation comprising complex of nucleic acid molecule and collagen |
| US7838502B2 (en) * | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
| EP1900380B1 (de) * | 2005-05-25 | 2013-03-27 | Cellmid Limited | Pharmazeutische zusammensetzung für okklusive gefässerkrankungen |
| EP1921153A4 (de) * | 2005-07-22 | 2009-07-08 | Koken Kk | Zelltransfektions-array zur verwendung bei der transfektion |
| WO2007107774A2 (en) * | 2006-03-22 | 2007-09-27 | Cartela R & D Ab | Integrin alpha-10 subunit as therapeutic target and diagnostic/prognostic marker for cancer |
| US20100105762A1 (en) * | 2007-02-16 | 2010-04-29 | Ryuichi Morishita | Therapeutic agent for periodontal disease and alveolar bone loss due to surgery |
| JP5789927B2 (ja) * | 2010-07-30 | 2015-10-07 | Jnc株式会社 | 放射線照射コラーゲン様ペプチドを用いた核酸導入法 |
| WO2013102878A2 (en) | 2012-01-05 | 2013-07-11 | Department Of Biotechnology (Dbt) | Fat1 gene in cancer and inflammation |
| WO2021041870A1 (en) * | 2019-08-30 | 2021-03-04 | University Of Florida Research Foundation | Aptamer assemblies for protein crosslinking |
| WO2022120338A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Florida Research Foundation, Inc. | Aptamer assemblies for protein crosslinking |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5115094B2 (de) * | 1972-11-01 | 1976-05-14 | ||
| JPH0712375B2 (ja) * | 1986-11-17 | 1995-02-15 | 株式会社高研 | 移植組成物及びその製造方法 |
| US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
| JPS6416581A (en) | 1987-07-09 | 1989-01-20 | Rikagaku Kenkyusho | Frozen animal cell and production thereof |
| JPH01157388A (ja) | 1987-12-11 | 1989-06-20 | Mitsubishi Heavy Ind Ltd | 形質転換方法 |
| US5078997A (en) * | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
| US5936035A (en) * | 1988-11-21 | 1999-08-10 | Cohesion Technologies, Inc. | Biocompatible adhesive compositions |
| US5614587A (en) * | 1988-11-21 | 1997-03-25 | Collagen Corporation | Collagen-based bioadhesive compositions |
| JP3187410B2 (ja) | 1989-08-10 | 2001-07-11 | 住友製薬株式会社 | 脳内投与用徐放性製剤 |
| JP2789115B2 (ja) | 1989-09-07 | 1998-08-20 | 株式会社高研 | 可溶性コラーゲンパウダーを担体とする粒状医薬徐放剤の製造方法 |
| US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| EP1484412A3 (de) | 1989-12-22 | 2007-10-17 | Laboratoires Serono SA | Eukarotische Zellinie mit einem aktivierten endogenen Gen und deren Verwendungen |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| JP2666535B2 (ja) | 1990-08-07 | 1997-10-22 | 東洋紡績株式会社 | 大腸菌のコンピテントセル化緩衝液および大腸菌のコンピテントセル化方法 |
| FR2694895B1 (fr) * | 1992-08-20 | 1994-11-10 | Coletica | Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification. |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| FI955720A0 (fi) * | 1993-05-28 | 1995-11-27 | Chiron Corp | Urokinaasireseptoriaktiivisuuden peptidi-inhibiittoreita |
| JPH09502191A (ja) * | 1993-09-09 | 1997-03-04 | シエーリング アクチエンゲゼルシヤフト | 作用物質およびガスを含有する微粒子 |
| CA2140053C (en) * | 1994-02-09 | 2000-04-04 | Joel S. Rosenblatt | Collagen-based injectable drug delivery system and its use |
| US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
| US5583034A (en) * | 1994-02-22 | 1996-12-10 | La Jolla Institute For Allergy And Immunology | Enhancement of adoptosis using antisense oligonucleotides |
| US5844107A (en) * | 1994-03-23 | 1998-12-01 | Case Western Reserve University | Compacted nucleic acids and their delivery to cells |
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| WO1996000295A1 (en) * | 1994-06-27 | 1996-01-04 | The Johns Hopkins University | Targeted gene delivery system |
| NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| GB9422495D0 (en) | 1994-11-08 | 1995-01-04 | Medical Res Council | DNA transfer method |
| ES2293648T3 (es) | 1995-07-03 | 2008-03-16 | Koken Co., Ltd. | Preparaciones de genes que contienen atelocolageno. |
| US6998268B2 (en) * | 1995-07-03 | 2006-02-14 | Dainippon Sumitomo Pharma Co. Ltd. | Gene preparations |
| JP3867160B2 (ja) | 1995-07-03 | 2007-01-10 | 大日本住友製薬株式会社 | 遺伝子製剤 |
| EP0859636A4 (de) | 1995-10-23 | 2002-05-02 | Hyal Pharmaceutical Australia | Hyaluronsäure als dna träger für die gentherapie sowie vegf antisense-dna zur behandlung abnormaler netzhautvaskularisierung |
| CN100390290C (zh) | 1995-11-13 | 2008-05-28 | 宝生物工程株式会社 | 用逆转录病毒将基因转入靶细胞的方法 |
| PT2111876E (pt) * | 1995-12-18 | 2011-12-23 | Angiodevice Internat Gmbh | Composições de polímero reticulado e seus métodos de utilização |
| AU728146B2 (en) * | 1996-03-14 | 2001-01-04 | Immune Response Corporation, The | Targeted delivery of genes encoding interferon |
| US5874006A (en) * | 1996-10-31 | 1999-02-23 | Matrix Pharmaceutical, Inc. | Aseptic collagen concentration process |
| US6042820A (en) * | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6218112B1 (en) * | 1996-12-23 | 2001-04-17 | Cobra Therapeutics Limited | Optimization of gene delivery and gene delivery system |
| US6524613B1 (en) * | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
| IT1293088B1 (it) | 1997-07-10 | 1999-02-11 | Isi Ist Sierovaccinogeno Ital | Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in |
| JPH11127843A (ja) | 1997-10-27 | 1999-05-18 | Sumitomo Bakelite Co Ltd | 培養用着色容器 |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| EP1054694A2 (de) * | 1998-02-13 | 2000-11-29 | Selective Genetics, Inc. | Gleichzeitige strömungsdurchmischung zur herstellung von zusammensetzungen, die gentherapievektoren enthalten |
| US7052875B1 (en) * | 1998-05-22 | 2006-05-30 | Sumitomo Pharmaceutical Company, Limited | Stable gene preparations |
| JP3587438B2 (ja) | 1999-01-14 | 2004-11-10 | 住友ベークライト株式会社 | 培養細胞凍結用マルチウェルプレート |
| JP3557924B2 (ja) * | 1998-12-10 | 2004-08-25 | トヨタ自動車株式会社 | 電動機制御装置及び電動機制御方法 |
| TR199901199A2 (xx) | 1999-05-31 | 2001-09-21 | Kocagöz Tanil | Bakteri transformasyon kiti |
| JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
| EP2363133A1 (de) * | 2000-03-31 | 2011-09-07 | Trustees of Boston University | Zusammensetzung enhalted DNA-Fragmente und ihre medizinischen und kosmetischen Verwendungen |
| JP2001335512A (ja) | 2000-05-23 | 2001-12-04 | Yamanouchi Pharmaceut Co Ltd | 遺伝子導入のための微粒子 |
| JP5118285B2 (ja) * | 2000-06-20 | 2013-01-16 | 大日本住友製薬株式会社 | オリゴヌクレオチド導入製剤 |
| JP2002325572A (ja) | 2000-12-25 | 2002-11-12 | Univ Osaka | 外来物質の導入方法 |
| ATE429930T1 (de) | 2001-06-20 | 2009-05-15 | Dainippon Sumitomo Pharma Co | Verfahren zur förderung des nukleinsäuretransfers |
| JP4022614B2 (ja) | 2002-03-25 | 2007-12-19 | 国立大学法人大阪大学 | 新規なバイオビーズの作製方法 |
| ITMI20021444A1 (it) | 2002-07-01 | 2004-01-02 | Danieli Off Mecc | Tubo forma spire |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| WO2004022075A1 (en) * | 2002-09-04 | 2004-03-18 | Novartis Ag | Treatment of neurological disorders by dsrna adminitration |
| JPWO2004026343A1 (ja) * | 2002-09-20 | 2006-01-12 | 住友製薬株式会社 | 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤 |
| CA2504926C (en) * | 2002-11-01 | 2014-01-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
| AU2004205895B2 (en) * | 2003-01-16 | 2009-02-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of ICAM-1 |
| US8227434B1 (en) * | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
| CN1946734B (zh) * | 2004-02-26 | 2012-07-18 | 贝勒研究院 | 系统性治疗关节炎的组合物和方法 |
| RU2584609C2 (ru) * | 2004-09-28 | 2016-05-20 | Кварк Фармасьютикалс, Инк. | Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности |
| WO2006042396A1 (en) * | 2004-10-22 | 2006-04-27 | Universite Laval | Modulation of neuroglia-derived bdnf in the treatment and prevention of pain |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| WO2007082899A1 (en) * | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| US8106024B2 (en) * | 2006-06-16 | 2012-01-31 | Taisho Pharmaceutical Co., Ltd. | Method of treating cancer with an RPN2 gene expression inhibitor |
| CA2658550C (en) * | 2006-07-21 | 2018-06-19 | Silence Therapeutics Ag | Means for inhibiting the expression of protein kinase 3 |
| WO2008028085A2 (en) * | 2006-08-30 | 2008-03-06 | The Board Of Trustees Of The University Of Illinois | Modulation of mlck-l expression and uses thereof |
| CA2665202A1 (en) * | 2006-10-02 | 2008-04-10 | Aprea Ab | Compounds and methods |
| US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
| JP2013512677A (ja) * | 2009-12-04 | 2013-04-18 | オプコ オプサルミクス、エルエルシー | Ｖｅｇｆの阻害のための組成物および方法 |
-
2002
- 2002-06-20 AT AT02741206T patent/ATE429930T1/de active
- 2002-06-20 US US10/481,511 patent/US8742091B2/en not_active Expired - Lifetime
- 2002-06-20 ES ES02741206T patent/ES2324525T3/es not_active Expired - Lifetime
- 2002-06-20 CN CNB028164008A patent/CN1313158C/zh not_active Expired - Fee Related
- 2002-06-20 DK DK02741206T patent/DK1407787T3/da active
- 2002-06-20 KR KR1020037016627A patent/KR100888566B1/ko not_active Expired - Fee Related
- 2002-06-20 WO PCT/JP2002/006137 patent/WO2003000297A1/ja not_active Ceased
- 2002-06-20 CA CA2451603A patent/CA2451603C/en not_active Expired - Fee Related
- 2002-06-20 PT PT02741206T patent/PT1407787E/pt unknown
- 2002-06-20 EP EP02741206A patent/EP1407787B1/de not_active Expired - Lifetime
- 2002-06-20 JP JP2003506939A patent/JP4081436B2/ja not_active Expired - Lifetime
- 2002-06-20 DE DE60232149T patent/DE60232149D1/de not_active Expired - Lifetime
-
2009
- 2009-09-04 US US12/554,846 patent/US20100081202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8742091B2 (en) | 2014-06-03 |
| CA2451603C (en) | 2012-07-10 |
| JPWO2003000297A1 (ja) | 2005-04-07 |
| KR100888566B1 (ko) | 2009-03-12 |
| WO2003000297A1 (fr) | 2003-01-03 |
| EP1407787A4 (de) | 2006-02-08 |
| ES2324525T3 (es) | 2009-08-10 |
| JP4081436B2 (ja) | 2008-04-23 |
| DK1407787T3 (da) | 2009-06-02 |
| EP1407787A1 (de) | 2004-04-14 |
| PT1407787E (pt) | 2009-07-07 |
| US20100081202A1 (en) | 2010-04-01 |
| CN1622831A (zh) | 2005-06-01 |
| DE60232149D1 (de) | 2009-06-10 |
| EP1407787B1 (de) | 2009-04-29 |
| KR20040023622A (ko) | 2004-03-18 |
| US20040266004A1 (en) | 2004-12-30 |
| CA2451603A1 (en) | 2003-01-03 |
| CN1313158C (zh) | 2007-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60232149D1 (de) | Verfahren zur förderung des nukleinsäuretransfers | |
| JP6986103B2 (ja) | 高スループット単一細胞トランスクリプトームライブラリーならびにその作製方法および使用方法 | |
| Jafary et al. | Osteoblast differentiation on collagen scaffold with immobilized alkaline phosphatase | |
| Liu et al. | Effect of 3D scaffold and dynamic culture condition on the global gene expression profile of mouse embryonic stem cells | |
| Dudakovic et al. | High‐resolution molecular validation of self‐renewal and spontaneous differentiation in clinical‐grade adipose‐tissue derived human mesenchymal stem cells | |
| Mademtzoglou et al. | Cellular localization of the cell cycle inhibitor Cdkn1c controls growth arrest of adult skeletal muscle stem cells | |
| Herbert et al. | Chicken double-stranded RNA adenosine deaminase has apparent specificity for Z-DNA. | |
| Satija et al. | Mesenchymal stem cells: molecular targets for tissue engineering | |
| Kriukienė et al. | 5-Hydroxymethylcytosine: the many faces of the sixth base of mammalian DNA | |
| Rood et al. | Genomic organization and chromosome localization of the human cathepsin K gene (CTSK) | |
| Haudenschild et al. | Differential expression of multiple genes during articular chondrocyte redifferentiation | |
| Robinson et al. | MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research | |
| GB2409274A (en) | Trap-tagging: a novel method for the identification and purification of RNA-protein complexes | |
| Xu et al. | Delta‐like 2 negatively regulates chondrogenic differentiation | |
| Helland et al. | Properties and mechanism of action of eukaryotic 3-methyladenine-DNA glycosylases | |
| Takahashi et al. | Effects of osteogenic induction on mesenchymal cells from fetal and maternal parts of human placenta | |
| Pih et al. | Isolation of molecular markers for salt stress responses in Arabidopsis thaliana | |
| Wang et al. | Wnt Signaling Modulates Routes of Retinoic Acid-Induced Differentiation of Embryonic Stem Cells | |
| Lopp et al. | 2′, 5′-oligoadenylate synthetase from a lower invertebrate, the marine sponge Geodia cydonium, does not need dsRNA for its enzymatic activity | |
| JP2022023684A (ja) | イヌ間葉系幹細胞培養用培地、イヌ間葉系幹細胞の培養方法及びイヌ間葉系幹細胞の製造方法 | |
| Zhang et al. | ceRNA Profiling Reveals circSAMD4A Promoted Porcine Adipocytes Differentiation via Targeting miR‐127/PRKAR2B | |
| Chung | Spot the difference: Solving the puzzle of hidden pictures in the lizard genome for identification of regeneration factors | |
| US20230100105A1 (en) | Regulatory elements in the genome | |
| Prasad et al. | ADP-ribosylation of heterogeneous ribonucleoproteins in HeLa cells | |
| US6846624B1 (en) | Expression cloning process for gene coding for a zinc-binding protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1407787 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |